drugset
drugset / Trial / NCT03435276

Multiple-ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD9977 in Healthy Male Subjects

NCT03435276 ↗

Phase 1 Completed 27 enrolled AstraZeneca Parexel · collab
RandomizedParallel-groupSingle-blindTreatment

Summary

This is a randomized, single-blind, placebo-controlled study conducted on healthy male subjects at a single study center to assess the safety, tolerability and the pharmacokinetics of AZD9977 following multiple-ascending oral doses at steady state

Timeline

Start
2018-02-27
Primary completion
2018-06-13
Completion
2018-06-13

Drugs

EvaluationDrugModalityDoseRoute
Subject balcinrenone Small molecule 50 mg Oral
Subject balcinrenone Small molecule 150 mg Oral
Subject balcinrenone Small molecule 300 mg Oral

Indications

No indication recorded.